Pfizer Pays $34.7M To Settle Genotropin Charges

Law360, New York (April 2, 2007, 12:00 AM EDT) -- Pfizer Inc. has agreed to pay fines of $34.7 million to settle allegations two subsidiaries engaged in illegal off-label marketing and paid kickbacks to a vendor to boost sales of human growth hormone Genotropin, the drug maker said Monday.

Two subsidiaries of Pfizer unit Pharmacia reached separate settlements with the U.S. Department of Justice for activities that occurred at Pharmacia before it was acquired by Pfizer in 2003, Pfizer said.

One subsidiary—Pharmacia & Upjohn Company Inc.—will plead guilty to a single count of offering to an...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.